AtaiBeckley Secures FDA Nod for Phase 3 Depression Trial, Eyes 2029 Runway
AtaiBeckley advances psychedelic depression treatment to Phase 3 with $220.7M cash runway through early 2029, plus positive anxiety trial data.
ATAIPhase 3 clinical trialFDA approval